BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar
- None.
- None.
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Dr. Juan Felipe Beltrán, Director of AI, Machine Learning, and Innovation, will be the featured speaker at the upcoming XTalks webinar: AI in Bioinformatics: Overcoming Pitfalls in Statistical, ML and Generative AI Approaches.
Vin Singh, Founder and CEO of BullFrog AI, commented, "Dr. Beltrán’s featured participation in the XTalks webinar not only highlights our leadership position in AI-driven bioinformatics but also emphasizes BullFrog AI’s dedication to addressing critical scientific challenges that directly impact the efficiency and success of drug development pipelines. Investors recognize the significant market opportunity in enhancing drug discovery processes, and showcasing BullFrog AI’s innovative capabilities supports our strategic vision and fortifies our position within this rapidly growing sector."
Join Dr. Juan Felipe Beltrán, a leading scientist and software engineer with deep expertise in machine learning, algorithm development, and bioinformatics, for an insightful webinar exploring the critical yet often overlooked pitfalls in AI-driven bioinformatics workflows. Drawing on his extensive contributions to proteomics, genomics, and public health challenges like COVID-19, Dr. Beltrán will highlight how even sophisticated computational methods can falter without careful attention to analytical nuance.
This session will focus on enhancing the accuracy and reproducibility of bioinformatics analyses by addressing three key issues: the mismanagement of compositional data, the overinterpretation of machine learning feature importance, and the misapplication of generative AI for biological ranking and prioritization. Attendees will gain practical insights to strengthen their data science foundations, improve AI model reliability, and future-proof their bioinformatics strategies in an increasingly complex research environment.
Dr. Beltrán’s proven track record of advancing complex bioinformatics solutions significantly reinforces BullFrog AI’s proprietary bfLEAP™ platform and flagship BullFrog Data Networks™, which are designed to empower biopharma companies by delivering actionable insights from complex, high-dimensional biological data. BullFrog AI’s solutions directly address the critical challenge in biopharma, where only
Interested professionals, including bioinformaticians, biostatisticians, data scientists, and translational scientists, are encouraged to register for the webinar to gain practical strategies for mitigating pitfalls in AI-powered bioinformatics workflows, ultimately improving decision-making and increasing confidence in analytical results.
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™ and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
What will Dr. Juan Felipe Beltrán discuss in the BullFrog AI (BFRG) XTalks webinar?
What is the current success rate for drugs entering Phase 1 clinical trials according to BullFrog AI (BFRG)?
What are BullFrog AI's (BFRG) main technology platforms?
Who is the target audience for BullFrog AI's (BFRG) XTalks webinar?
